In vitro fungicidal efficacy of coclopirox;Activité fongicide in vitro du ciclopirox

Journal de Mycologie Medicale

Volumn 14, Issue 2, 2004, Pages 78-82

  Jomard, P ^a   Luc, J ^a   Roques, C ^a  

^a UFR des Sciences Pharmaceutiques   (France)

Author keywords

Ciclopirox; Dermatophytes; Fungicidal efficacy; Moulds; Yeasts

Indexed keywords

CICLOPIROX; CICLOPIROXOLAMINE; FUNGICIDE; PYRIDINOL; PYRROLE DERIVATIVE;

ABSIDIA; ARTICLE; CANDIDA ALBICANS; CELL DENSITY; CLADOSPORIUM; CLADOSPORIUM CLADOSPORIOIDES; CONTROLLED STUDY; DERMATOPHYTE; DRUG EFFICACY; FUNGICIDAL ACTIVITY; FUNGUS; FUNGUS GROWTH; HENDERSONULA TORULOIDEA; IN VITRO STUDY; MOULD; NONHUMAN; PENICILLIUM; PENICILLIUM VERRUCULOSUM; SCANNING ELECTRON MICROSCOPY; SCOPULARIOPSIS BREVICAULIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; VALIDATION PROCESS; YEAST;

ABSIDIA; ABSIDIA CORYMBIFERA; ARTHRODERMA BENHAMIAE; ARTHRODERMATACEAE; CANDIDA; CANDIDA ALBICANS; CLADOSPORIUM; CLADOSPORIUM CLADOSPORIOIDES; FUNGI; PENICILLIUM; PENICILLIUM VERRUCOSUM; PENICILLIUM VERRUCULOSUM; SCOPULARIOPSIS; SCOPULARIOPSIS BREVICAULIS; TRICHOPHYTON; TRICHOPHYTON INTERDIGITALE; TRICHOPHYTON RUBRUM;

EID: 3142762505     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. AFNOR. Recueil des normes « Antiseptiques et désinfectants », 1991.
2. Baran R. Ciclopirox nail lacquer: the first prescription topical therapy for onychomycosis, Introduction. J Am Acad Dermatol 2000;43:S55-6.
3. Bohn M, Kraemer K. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J Am Podiatr Med Assoc 2000;90:491-4.
4. Ceschin-Roques C, Hanel H, Pruja-Bougaret S, Luc J, Vandermander J, Michel G. Ciclopirox nail lacquer 8%:in vivo penetration into and through nails and in vitro effect. Skin Pharmacol 1991;4:89-94.
5. Chabasse D, Baran R, De Chauvin MF. Onychomycosis I: epidemiology and etiology. J Mycol Méd 2000;10:177-90.
6. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11:415-429.
7. En T, Schell T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997;36:788-92.
8. Galitz J. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report. Cutis 2001;68:23-4.
9. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc 2000;90:495-501.
10. Gupta AK. Ciclopirox nail lacquer: a brush with onychomycosis. Cutis 2001;68:16.
11. Gupta AK. Ciclopirox: an overview. Int J Dermatol 2001;40:305-10.
12. Hainer BL. Dermatophyte infections. Am Fam Physician 2003;67:101-8.
13. Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother 1998;42:741-5.
14. Leem SH, Park JE, Kim IS, Chae JY, Sugino A, Sunwoo Y. The possible mechanism of action of ciclopiro olamine in the yeast Saccharomyces cerevisiae. Mol Cells 2003;15:55-61.
15. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. 1998;42:3018-21.
16. Markus A. Hydroxy-pyridones: Outstanding biological properties. In: Hydroxy-pyridones as antifungal agents with special emphasis on onychomycosis. Ed. Shuster S. Springer Berlin, 1999:1-10.
17. Niewerth M, Schaller M, Korting HC, Hube B. Mode of action of ciclopiroxolamine on Candida albicans. Mycoses 2002;45:63-8.
18. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. Ciclopirox olamine treatment affects the expression of Candida albicans genes encoding virulence gfactors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003;47:1805-17.
19. Reitze HK, Seitz KA, Dannhorn DR, Hänel H, Bohn M. Enzyme histochemical investigations of Candida albicans after treatment with rilopirox, a novel fungicidal hydroxy-pyridone. In: Hydroxy-pyridones as antifungal agents with special emphasis on onychomycosis. Ed. Shuster S. Springer Berlin, 1999:11-7.
20. Rigopoulos D, Katsiboulas V, Koumantaki E, Emmanouil P, Papanicolaou A, Katsambas A. Epidemiology of onychomycosis in Southern Greece. Int J Dermatol 1998;37:925-8.
21. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001;68:17-22.
22. Ta AK. Onychomycosis in the elderly. Drugs Aging 2000:397-407.
23. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response treatment of 59 cases. J Am Acad Dermatol 2000;42:217-24.